Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
Company Contact | |
Address: | Suite 1430, 800 West Pender St. VANCOUVER BC V6C 2V6 |
Tel: | N/A |
Website: | https://www.cognetivity.com |
IR: | See website |
Key People | ||
Sina Habibi Chief Executive Officer, Director | Thomas Roger Sawyer Chief Financial Officer, Chief Operating Officer, Corporate Secretary, Director | Seyed Madhi Khaligh Razavi Chief Scientific Officer | Christos Kalafatis Chief Medical Officer, Director |
Business Overview |
Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial and consumer environments for potentially allowing early diagnosis of dementia. The Company's ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from providing a measure of cognitive function, to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The Company serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe. |
Financial Overview |
For the nine months ended 31 October 2023, Cognetivity Neurosciences Ltd revenues increased from C$0K to C$54K. Net loss increased 25% to C$6.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Accretion expenses increase from C$116K to C$3.6M (expense), Other income decrease from C$209K (income) to C$0K. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $0.37M as of Oct 31, 2023 |
Annual revenue (TTM): | $0.10M as of Oct 31, 2023 |
EBITDA (TTM): | -$4.40M as of Oct 31, 2023 |
Net annual income (TTM): | -$8.64M as of Oct 31, 2023 |
Free cash flow (TTM): | -$3.88M as of Oct 31, 2023 |
Net Debt Last Fiscal Year: | $1.35M as of Oct 31, 2023 |
Shares outstanding: | 89,556,611 as of Oct 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |